Walleye Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Walleye Capital’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-83,919	Closed	-$867K	–	5423
2023 Q2	$867K	Buy	83,919 +20,064	+31%	+$205K	﹤0.01%	1969
2023 Q1	$647K	Hold	63,855	–	–	0.01%	1491
2022 Q4	$635K	Buy	63,855 +19,406	+44%	+$192K	0.01%	1304
2022 Q3	$433K	Hold	44,449	–	–	0.01%	1570
2022 Q2	$432K	Hold	44,449	–	–	0.01%	1119
2022 Q1	$431K	Hold	44,449	–	–	0.01%	1090
2021 Q4	$431K	Sell	44,449 -7,948	-15%	-$77.3K	0.01%	1072
2021 Q3	$508	Buy	+52,397	New	+$511K	0.01%	779

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Walleye Capital's NKGN Position: Q3 2023 in Review

Walleye Capital sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 83,919 shares — an estimated $867K sold.

Walleye Capital first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $867K in Q2 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

Walleye Capital reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 83,919 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $867K.
Walleye Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Walleye Capital's NKGen Biotech, Inc. Common Stock position peaked at $867K in Q2 2023.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.